The FDA completed the first-cycle review of an Abbreviated New Drug Application (ANDA) involving NRx Pharmaceuticals and Teva.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA completed the first-cycle review of an Abbreviated New Drug Application (ANDA) involving NRx Pharmaceuticals and Teva.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Related events
- Teva's acquired product is currently undergoing review by the FDA.
- Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Teva Pharmaceutical Industries discussed company strategy at an event hosted by Morgan Stanley.